Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Authors
Keywords
-
Journal
Journal of Hematology & Oncology
Volume 13, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-09-03
DOI
10.1186/s13045-020-00956-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Enhancing global access to cancer medicines
- (2020) Javier Cortes et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
- (2020) John D. Martin et al. Nature Reviews Clinical Oncology
- Therapy-induced senescence — an induced synthetic lethality in liver cancer?
- (2020) Katharina Wolter et al. Nature Reviews Gastroenterology & Hepatology
- The antitumorigenic roles of BRCA1–BARD1 in DNA repair and replication
- (2020) Madalena Tarsounas et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Target gene-independent functions of MYC oncoproteins
- (2020) Apoorva Baluapuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): Clinical candidate for cancer therapy
- (2020) Lukas Gorecki et al. PHARMACOLOGY & THERAPEUTICS
- A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib
- (2020) Wayne D. Blosser et al. Oncotarget
- Targeting the MAPK Pathway in KRAS-Driven Tumors
- (2020) Matthias Drosten et al. CANCER CELL
- CHK1 Inhibition Is Synthetically Lethal with Loss of B-Family DNA Polymerase Function in Human Lung and Colorectal Cancer Cells
- (2020) Rebecca F. Rogers et al. CANCER RESEARCH
- Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism
- (2020) Di Yu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A high-content RNAi screen reveals multiple roles for long noncoding RNAs in cell division
- (2020) Lovorka Stojic et al. Nature Communications
- Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer
- (2020) Anniina Färkkilä et al. Nature Communications
- ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma
- (2020) Hailong Sheng et al. Journal for ImmunoTherapy of Cancer
- Chk1-mediated Cdc25A degradation as a critical mechanism for normal cell-cycle progression
- (2019) Hidemasa Goto et al. JOURNAL OF CELL SCIENCE
- Delivery technologies for cancer immunotherapy
- (2019) Rachel S. Riley et al. NATURE REVIEWS DRUG DISCOVERY
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- Multiple Defects Sensitize p53-Deficient Head and Neck Cancer Cells to the WEE1 Kinase Inhibition
- (2019) Ahmed Diab et al. MOLECULAR CANCER RESEARCH
- Data mining for mutation-specific targets in acute myeloid leukemia
- (2019) Brooks Benard et al. LEUKEMIA
- Inhibiting Wee1 and ATR kinases produces tumor-selective synthetic lethality and suppresses metastasis
- (2019) Amirali B. Bukhari et al. JOURNAL OF CLINICAL INVESTIGATION
- EZH2 cooperates with gain‐of‐function p53 mutants to promote cancer growth and metastasis
- (2019) Yu Zhao et al. EMBO JOURNAL
- Polo-like Kinase 1 Inhibition as a Therapeutic Approach to Selectively Target BRCA1-Deficient Cancer Cells by Synthetic Lethality Induction
- (2019) Sofía Carbajosa et al. CLINICAL CANCER RESEARCH
- Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
- (2019) Charlie Gourley et al. JOURNAL OF CLINICAL ONCOLOGY
- Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens
- (2019) Fiona M. Behan et al. NATURE
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- A novel synthetic-genetic-array–based yeast one-hybrid system for high discovery rate and short processing time
- (2019) Chung-Shu Yeh et al. GENOME RESEARCH
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage
- (2019) Sara Giovannini et al. NUCLEIC ACIDS RESEARCH
- Nbn−Mre11 interaction is required for tumor suppression and genomic integrity
- (2019) Jun Hyun Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Pellino1 regulates reversible ATM activation via NBS1 ubiquitination at DNA double-strand breaks
- (2019) Geun-Hyoung Ha et al. Nature Communications
- Exploiting interconnected synthetic lethal interactions between PARP inhibition and cancer cell reversible senescence
- (2019) Hubert Fleury et al. Nature Communications
- Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition
- (2019) Priya Patel et al. OncoImmunology
- A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses
- (2019) Alexandra S. Zimmer et al. Journal for ImmunoTherapy of Cancer
- LMO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL
- (2019) Salma Parvin et al. CANCER CELL
- Genome-wide CRISPR-Cas9 screen reveals selective vulnerability of ATRX-mutant cancers to WEE1 inhibition
- (2019) Junbo Liang et al. CANCER RESEARCH
- Dual Inhibition of GLUT1 and the ATR/CHK1 Kinase Axis Displays Synergistic Cytotoxicity in KRAS-Mutant Cancer Cells
- (2019) Johanna Erber et al. CANCER RESEARCH
- Prospects for combining immune checkpoint blockade with PARP inhibition
- (2019) Anping Li et al. Journal of Hematology & Oncology
- CC-115, a dual mTOR/DNA-PK inhibitor in clinical trial, is a substrate of ABCG2, a risk factor for CC-115 resistance
- (2019) Jenny Beebe et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
- (2019) Triparna Sen et al. Journal of Thoracic Oncology
- FDA-approved drug screen identifies proteasome as a synthetic lethal target in MYC-driven neuroblastoma
- (2019) Jingchao Wang et al. ONCOGENE
- TAG-RNAi overcomes off-target effects in cancer models
- (2019) Julien Champagne et al. ONCOGENE
- Upregulation of Myt1 Promotes Acquired Resistance of Cancer Cells to Wee1 Inhibition
- (2019) Cody W. Lewis et al. CANCER RESEARCH
- AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
- (2019) Jacqueline H. L. Fok et al. Nature Communications
- The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-a]pyridin-6-yl)amino]-9-(tetrahydro-2H-pyran-4-yl)-7,9-dihydro-8H-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor
- (2019) Frederick W. Goldberg et al. JOURNAL OF MEDICINAL CHEMISTRY
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
- (2019) Alice Bradbury et al. PHARMACOLOGY & THERAPEUTICS
- Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma
- (2019) Kewen Hu et al. JOURNAL OF CLINICAL INVESTIGATION
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer
- (2018) Yunxiao Meng et al. CANCER LETTERS
- FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
- (2018) Gwynn Ison et al. CLINICAL CANCER RESEARCH
- Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma
- (2018) David S. Hong et al. CLINICAL CANCER RESEARCH
- Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors
- (2018) Anish Thomas et al. JOURNAL OF CLINICAL ONCOLOGY
- Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study
- (2018) Jung-Min Lee et al. LANCET ONCOLOGY
- The Histone Chaperones ASF1 and CAF-1 Promote MMS22L-TONSL-Mediated Rad51 Loading onto ssDNA during Homologous Recombination in Human Cells
- (2018) Ting-Hsiang Huang et al. MOLECULAR CELL
- Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer
- (2018) Yonathan Lissanu Deribe et al. NATURE MEDICINE
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy
- (2018) Yanxin Lu et al. PHARMACOLOGY & THERAPEUTICS
- ATR/CHK1 inhibitors and cancer therapy
- (2018) Zhaojun Qiu et al. RADIOTHERAPY AND ONCOLOGY
- Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
- (2018) Stephen J. Pettitt et al. Nature Communications
- Synthetic Lethality-based Identification of Targets for Anticancer Drugs in the Human Signaling Network
- (2018) Lei Liu et al. Scientific Reports
- AZD1775 Increases Sensitivity to Olaparib and Gemcitabine in Cancer Cells with p53 Mutations
- (2018) Xiangbing Meng et al. Cancers
- Yeast genetic interaction screens in the age of CRISPR/Cas
- (2018) Neil R. Adames et al. CURRENT GENETICS
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors
- (2018) Sung-Bau Lee et al. Science Advances
- Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules
- (2018) Yusuke Matsuno et al. Cancers
- Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 (BRCA2) Mutation
- (2018) Chong Du et al. ACS Nano
- Activated kinase screening identifies the IKBKE oncogene as a positive regulator of autophagy
- (2018) Margherita Leonardi et al. Autophagy
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- A Phase II Study of Talazoparib After Platinum or Cytotoxic Nonplatinum Regimens in Patients With Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
- (2018) Nicholas C. Turner et al. CLINICAL CANCER RESEARCH
- Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of preclinical pediatric tumor models
- (2018) Caitlin D Lowery et al. CLINICAL CANCER RESEARCH
- Talazoparib: First Global Approval
- (2018) Sheridan M. Hoy DRUGS
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA
- (2018) Demis Menolfi et al. Nature Communications
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
- (2018) Liya Ding et al. Cell Reports
- CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells
- (2017) Gwenola Manic et al. GUT
- PARP inhibitors: Clinical utility and possibilities of overcoming resistance
- (2017) Benjamin G. Bitler et al. GYNECOLOGIC ONCOLOGY
- Cell-Cycle Therapeutics Come of Age
- (2017) Matthew Ingham et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Progress in PARP inhibitors beyond BRCA mutant recurrent ovarian cancer?
- (2017) Antonio González Martín LANCET ONCOLOGY
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Identifying synthetic lethal targets using CRISPR/Cas9 system
- (2017) Jaspreet Kaur Dhanjal et al. METHODS
- Loss of MLH1 sensitizes colon cancer cells to DNA-PKcs inhibitor KU60648
- (2017) Inga Hinrichsen et al. MOLECULAR CARCINOGENESIS
- Prediction of potent shRNAs with a sequential classification algorithm
- (2017) Raphael Pelossof et al. NATURE BIOTECHNOLOGY
- A synthetic lethal bullet
- (2017) Christian Rolfo et al. Nature Nanotechnology
- Synthetically lethal nanoparticles for treatment of endometrial cancer
- (2017) Kareem Ebeid et al. Nature Nanotechnology
- Synthetic lethality screens point the way to new cancer drug targets
- (2017) Asher Mullard NATURE REVIEWS DRUG DISCOVERY
- Marked for death: targeting epigenetic changes in cancer
- (2017) Sophia Xiao Pfister et al. NATURE REVIEWS DRUG DISCOVERY
- Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics
- (2017) Nina Frey et al. Nature Reviews Gastroenterology & Hepatology
- Synthetic lethality and cancer
- (2017) Nigel J. O'Neil et al. NATURE REVIEWS GENETICS
- The HSP90 chaperone machinery
- (2017) Florian H. Schopf et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma
- (2017) V Colicchia et al. ONCOGENE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors
- (2017) Anton G. Henssen et al. Science Translational Medicine
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
- (2017) David Quigley et al. Cancer Discovery
- Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
- (2017) Jane Goodall et al. Cancer Discovery
- Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality
- (2016) Tatyana S. Nekova et al. CELL CYCLE
- The Emerging Hallmarks of Cancer Metabolism
- (2016) Natalya N. Pavlova et al. Cell Metabolism
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells
- (2016) R. J. D. Reid et al. GENETICS
- Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer
- (2016) David Hong et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors
- (2016) Sergio Ruiz et al. MOLECULAR CELL
- CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes
- (2016) Bastiaan Evers et al. NATURE BIOTECHNOLOGY
- Systematic comparison of CRISPR/Cas9 and RNAi screens for essential genes
- (2016) David W Morgens et al. NATURE BIOTECHNOLOGY
- Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
- (2016) Angela George et al. Nature Reviews Clinical Oncology
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- A global genetic interaction network maps a wiring diagram of cellular function
- (2016) M. Costanzo et al. SCIENCE
- Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
- (2016) Xia Ding et al. Nature Communications
- Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK
- (2016) Jieqiong Wang et al. Nature Communications
- Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
- (2016) Jessica S. Brown et al. Cancer Discovery
- Prognostic and Predictive Value inKRASin Non–Small-Cell Lung Cancer
- (2016) Kevin Wood et al. JAMA Oncology
- CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
- (2016) Sara Costa-Cabral et al. PLoS One
- SiPAN: simultaneous prediction and alignment of protein–protein interaction networks
- (2015) Ferhat Alkan et al. BIOINFORMATICS
- ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
- (2015) M. Kwok et al. BLOOD
- Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
- (2015) Sophia X. Pfister et al. CANCER CELL
- A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
- (2015) Felix Dietlein et al. CELL
- FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy
- (2015) G. Kim et al. CLINICAL CANCER RESEARCH
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115
- (2015) Deborah S. Mortensen et al. JOURNAL OF MEDICINAL CHEMISTRY
- Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway
- (2015) Marwan Kwok et al. LANCET
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- High-throughput functional genomics using CRISPR–Cas9
- (2015) Ophir Shalem et al. NATURE REVIEWS GENETICS
- p53 in survival, death and metabolic health: a lifeguard with a licence to kill
- (2015) Flore Kruiswijk et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- PAXX, a paralog of XRCC4 and XLF, interacts with Ku to promote DNA double-strand break repair
- (2015) T. Ochi et al. SCIENCE
- ATR Mediates a Checkpoint at the Nuclear Envelope in Response to Mechanical Stress
- (2014) Amit Kumar et al. CELL
- Targeting BRCA1-BER deficient breast cancer by ATM or DNA-PKcs blockade either alone or in combination with cisplatin for personalized therapy
- (2014) Nada Albarakati et al. Molecular Oncology
- Cationic Lipid-Assisted Polymeric Nanoparticle Mediated GATA2 siRNA Delivery for Synthetic Lethal Therapy of KRAS Mutant Non-Small-Cell Lung Carcinoma
- (2014) Song Shen et al. MOLECULAR PHARMACEUTICS
- Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy
- (2014) Kilian V. M. Huber et al. NATURE
- Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors
- (2014) Y. Bian et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells
- (2014) Jing Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC
- (2014) F. Dietlein et al. Cancer Discovery
- Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy
- (2014) H. Al-Ahmadie et al. Cancer Discovery
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- (2013) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors
- (2013) Brooke M. Emerling et al. CELL
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- Chk1/2 Inhibition Overcomes the Cisplatin Resistance of Head and Neck Cancer Cells Secondary to the Loss of Functional p53
- (2013) M. A. Gadhikar et al. MOLECULAR CANCER THERAPEUTICS
- Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
- (2013) Jan R. Dörr et al. NATURE
- Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
- (2012) S. Ying et al. CANCER RESEARCH
- Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
- (2012) Michael Steckel et al. CELL RESEARCH
- Deregulated MYC expression induces dependence upon AMPK-related kinase 5
- (2012) Lidan Liu et al. NATURE
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- A Yeast GSK-3 Kinase Mck1 Promotes Cdc6 Degradation to Inhibit DNA Re-Replication
- (2012) Amy E. Ikui et al. PLoS Genetics
- MK-1775, a Novel Wee1 Kinase Inhibitor, Radiosensitizes p53-Defective Human Tumor Cells
- (2011) K. A. Bridges et al. CLINICAL CANCER RESEARCH
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
- (2010) Andrew Tutt et al. LANCET
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3
- (2010) Amy Baldwin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Redox Regulation of DNA Repair: Implications for Human Health and Cancer Therapeutic Development
- (2009) Meihua Luo et al. ANTIOXIDANTS & REDOX SIGNALING
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Synthetic Lethality — A New Direction in Cancer-Drug Development
- (2009) J. Dirk Iglehart et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-dependent protein kinase catalytic subunit modulates the stability of c-Myc oncoprotein
- (2008) Jing An et al. Molecular Cancer
- Single-strand break repair and genetic disease
- (2008) Keith W. Caldecott NATURE REVIEWS GENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now